NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$18.75 USD
+0.23 (1.24%)
Updated May 31, 2024 04:00 PM ET
After-Market: $18.76 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NAMS 18.75 +0.23(1.24%)
Will NAMS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NAMS
Jefferies sees 'key nuance' in comparing NewAmsterdam to AstraZeneca data
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2024 Update
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)